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TemperatureAbstract Many thermal distortions may accompany the profound extended analgesia of intrathe-
cal l agonists. Hypothermia is the commonest, but a syndrome including a profuse sweating was
also reported. Conservative management for this sweating extends patient suffering more than
6 h. Other treatment options showed variable success rates. In a case series, atropine sulfate showed
effective sweat suppression following intrathecal morphine 0.3 mg or fentanyl 25 mcg. Treatment
options and possible mechanisms of sweating are reviewed in relation to opioids, regional block
and general patient factors.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypothermia, commonly associates the analgesia of intrathecal
(IT) l agonist opioids [1]. In addition, a profuse sweating some-
times appears within a syndrome that starts about three hours
of injection, also comprising, feeling hotness, lethargy, itching,
nausea,vomiting,hypothermiawithout shiveringandsometimes
dysphoria [2–8]. However, patients are hemodynamically stable
with normal electrolytes, complete blood count, ECG, troponin,
serum cortisol and thyroid stimulating hormone and not
responding to aggressive warming measures [3,7].
The mechanism of this syndrome is not clear. Active treat-
ment options included naloxone [3] and lorazepam [4,6,7].
Atropine is suggested as an option in this study.1.1. Thermal effects of anesthesia
General [9] and regional anesthesia [10], as well as IT opioids
[11] highly increased the thermostatic inter-threshold range
thus intensifying hypothermia [12]. Opioids inhibit the warm-
sensitive neurons in the medial preoptic area of the hypothala-
mus which is the principle center for thermoregulation [13]. IT
morphine (Mo) can reach the opioid receptors in the hypotha-
lamus through cephalad spread within CSF causing new setting
of thermoregulatory center that the inter-threshold range was
above this new upper temperature threshold generating sweat-
ing [5]. Nevertheless, opioids exert a range of thermoregulatory
effects, depending upon various factors, such as animal species,
age, circadian rhythms, route of administration and dose [14].
2. Case series and results
The ﬁrst case involved in this study (Table 1, case1) managed
conservatively only, due to lack of experience with this
phenomenon. Knowledge regards this syndrome stimulated
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398 A. Mazyprospective search about further cases for trial evaluation of
atropine as a treatment for this sweating. Over two years
(2014–2015) observation attained more three cases (Table 2,
cases 2, 3, 4) among 217 consecutive patients underwent
lower limb orthopedic surgery under spinal anesthesia using
IT: 15–20 mg 0.5% heavy bupivacaine plus Mo 0.2–0.3 mg
in 32% of patients, or fentanyl 25 micrograms (mcg) in
68% of patients. Mean age was 34 years (range: 17–72).
Results revealed that the incidence of the profuse sweating
syndrome in these patients was 1.8%. Sweating started about
three hours after spinal injection. This syndrome was
detected intra operatively in all cases except case 4 (Table 2)
that was consulted six hours postoperatively due to profuse
sweating, vomiting and urine retention. Atropine was tried
in the last 3 cases as 0.5 mg increments. Atropine 1 mg was
promptly effective within minutes in discontinuing this sweat-
ing without recurrence. Subsequently temperature was rising
slowly. Tables 1 and 2 display the clinical, surgical and anes-
thetic data of these cases.3. Discussion
This study showed that atropine controlled the sweating fol-
lowing IT Mo or fentanyl. The incidence of the excessive
sweating in this study was 1.8%. Erdine et al. reported the
same rate of sweating after IT morphine [15]. Hess et al.
reported an incidence about 7% [4], the same as Paice et al.
[16]. This rate may be up to 9% with both transdermal fen-
tanyl and oral Mo [17] and up to 40% in patients on long-
term methadone treatment [18]. The treatment options and
possible etiologies will be discussed.
3.1. First: Treatment options
3.1.1. Atropine
Atropine effectively controlled the profuse sweating following
IT Mo or fentanyl in this study. The nerve supply of sweat
glands is mainly cholinergic [19] with a few adrenergic termi-
nals [20]. Acetylcholine is the main pre and postganglionic
transmitter of the sympathetic nervous supply of the sweat
glands [21], and hence the rationale of using atropine as an
anticholinergic greatly attenuates or abolishes sweating [22].
Atropine suppressed thermal and non-thermal sweating where
both types are cholinergic [23]. The cholinergic system is also
involved in Mo-induced hyperthermia [24].
Similarly, the anticholinergic hyoscine controlled the opi-
oids – induced sweating [25]. On the contrary, IT neostigmine
100 mcg, produced profuse sweating, agitation, nausea and
vomiting [26].
Atropine has the advantage of high end-organ efﬁcacy
whatever the mechanism of sweating. The tachycardia combin-
ing atropine may be beneﬁcial against the high degree of car-
diac vagal activity associated spinal anesthesia [27] or the
parasympathetic predominance associated Mo as conﬁrmed
by heart rate variability [28].
3.1.2. Naloxone
Thermal changes of l agonists are opioid receptor effects.
Naloxone antagonized sweating, hypothermia, sedation, pruri-
tus, nausea and vomiting [29,30]. On the other hand, naloxone
Table 2 Clinical, surgical and anesthetic data of atropine treated cases.
Patient
Age/sex
Medical
problems
Surgery/duration IT drugs Symptoms & signs Onset after spinal Treatment Treatment
eﬃcacy
Case 2 No Illizarov for fracture tibia/5 h 20 mg Bup Mild Itching 30 min
28 y/m +25 mcg fentanyl Sweating, 2.5 h Atropine 1 mg (+)
drowsiness,
BP 110/65,
HR 80/min
RBS 176 mg
Vomiting 2 h Propofol 30 mg (+)
Case 3 HTN Knee arthroplasty/3.33 h 20 mg Bup Sweating, 2.7 h Atropine 1 mg (+)
N&V, Metoclopramide 10 mg (+)
50 y/f +0.3 mg Mo Weakness,
Drowsiness
Case 4 No Ankle arthroscopy/1.5 h 15 mg Bup Hypothermia 2 h Conventional rewarming ()
(35.5 C)
32 y/m +0.2 mg Mo Sweating, consulted after 3.5 h Atropine 1 mg (+)
6 h
BP 110/70,
HR 88/min,
RR 17/min
Vomiting 3.5 h Granisetrone (+)
(4 times) 1 mg
Urine retention 4 h Catheterization (+)
F: female, m: male, y: years, h: hours, HTN: hypertension, Bup: Bupivacaine, Mo: Morphine, RBS: random blood sugar, N&V: Nausea & vomiting. Treatment Efﬁcacy for controlling the
symptoms: (+) Effective, () not effective, (±) partial control.
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400 A. Mazyutilization was associated with excessive shivering [3], and it
has a short duration of action [31].
3.1.3. Lorazepam
Lorazepam attenuated the thermal changes of IT opioids [4,7].
Benzodiazepines inhibit the inhibitor neurons in the preoptic
area of the anterior hypothalamus, releasing the dorsomedial
area of the hypothalamus, leading to activation of effector
neurons to increase body temperature [32]. Experimentally,
GABA-enhancing drugs attenuated Mo-induced hyperthermia
[33]. But lorazepam partially (80%) controlled the sweating
and hypothermia [4].
Actually the previous three treatment modalities are not
contradictory, where several neurotransmitters such as acetyl-
choline, serotonin, GABA and opioids are involved in ther-
moregulation [34].
3.1.4. Other drugs
Generally, nonsteroidal anti-inﬂammatory agents and steroids
have no clear beneﬁt to control this sweating [25].
Antihistamines showed a possible beneﬁt in two similar
patients [35]. Moreover, some antihistamines as diphenhy-
dramine can exhibit anticholinergic action [36].
Catecholamines augment sweating [37], but in a weaker rate
than the one triggered by cholinergic stimulation [38]. Antia-
drenergic drugs are supposed to be effective especially in
adrenergic mediated emotive sweating that is stimulated by
stress, anxiety, fear and pain. But b blockers are not effective
in treating sweating [39]. Ephedrine has a negligible contribu-
tion to sweating [38]. An exception to this rule was in patients
with complex regional pain syndrome, in whom increased
a-receptor sensitivity augments sweating [40]. This syndrome
can be precipitated by arthroscopic procedures of the knee
as a common cause [41].
3.2. Second: Possible etiologies of sweating
The mechanism of this sweating is not clear, but opioids are
mainly incriminated [2,3,5,7]. The cause of delayed onset and
why only few patients – not all – given IT l agonists display
this syndrome is not clear? So there may be an additional con-
tributing factors related to the opioids, regional anesthesia or
patient general factors.
The delayed onset was explained as the time elapsed until
cephalad spread of Mo to the hypothalamic opioid receptors
[3,5]. Although this well not explains why not all patients given
IT opioids develop this syndrome? In particular there is no
correlation to the dose, where this syndrome appeared after
either small dose (50 mcg) [42], or large dose (4 mg) [6]. There
is also a possibility that IT Mo acts directly on the spinal cord
generating these thermal effects [43].
The delay may correlate with the accumulation of the
metabolite morphine-3-glucuronide (M3G). The maximum
concentration of M3G in the CSF is three hours after intrac-
erebroventricular injection of morphine [44]. Moreover,
M3G produces the excitatory side effects of morphine [45] that
may explain the associated nausea, vomiting and itching [46].
Accumulation of serotonin may be a reason. Its level
increases 50% after Mo administration [47]. That occurs
through the opioid-mediated inhibition of GABA presynaptic
inhibitory effect on serotonin release [48]. Also serotonin isincreased by its reuptake inhibition with other piperidine opi-
oids such as fentanyl [49]. Co-administration of opioids with
other serotonergic drugs can precipitate serotonin syndrome.
These drugs are commonly used perioperatively, such as meto-
clopramide, ondansetron, granisetron, chlorpheniramine, gin-
seng, dextromethorphan and antidepressants for neuropathic
pain [50]. Serotonin syndrome is characterized by a triad of
mental state and neuromuscular tone alteration, plus auto-
nomic hyperactivity that can appear as diaphoresis without
fever [49].
Experimentally, IT Mo has a biphasic thermal pattern.
That high doses produce hypothermia by j-opioid receptors
stimulation [51], while the low doses produce hyperthermia
by l-opioid receptors activation, increasing thermoregulatory
set point, oxygen consumption and peripheral vasoconstriction
[52]. This hyperthermia is maximum at 2–3 h after subcuta-
neous morphine in rats [53]. But hyperthermia may appear
only in the presence of high ambient temperature [54]. The
profuse sweating in patients is associated with hypothermia,
proposing a central distortion by opioids rather than a ther-
moregulatory response [5].
The duration of thermal effects of IT morphine ranges from
6–7 h [4,7] to 22 h [2]. Regardless of the short duration of
action of fentanyl, its IT analgesia extends about ﬁve hours
[55].
Regional anesthesia may contribute to sweating through
triple factors: vasodilatation, blocked cold sensation and
apparently elevated leg temperature [56]. The brain interprets
this as a warming that results in heat loss. Fever without
infection may occur in association with regional block espe-
cially during labor [57] and post-operatively [58], where sweat-
ing is reduced in the blocked area, therefore passive
hyperthermia is induced if heat production exceeds heat loss.
But we can exclude these effects as sweating is associated with
hypothermia and it follows opioids and not bupivacaine
alone.
None of the general factors such as patient characteristics,
operative procedure, intraoperative ﬂuid administration, or
estimated blood loss was conclusive for anticipating the occur-
rence of sweating [2,3,5,7]. In addition many non-thermal fac-
tors can affect the central [59] and peripheral heat sensors [60].
The hypothalamus responds not only to changes in core
temperature but also to hormones, physical activity, endoge-
nous pyrogens and emotions [59].
Transient receptor potential (TRP) is the principal temper-
ature sensor [61]. The hot-activated receptors are non-selective
channels. They are gated by speciﬁc range of temperature, as
well as adenosine triphosphate and protons, also sensitized
directly by inﬂammatory mediators including growth factors,
peptides, lipids, neurotransmitters, chemokines and cytokines
and indirectly by binding to metabotropic receptors [60]. Mo
inhibits the cold receptor TRPM8 (M: melastatin) [62] and
TRPV1 (V: vanilloid) warm receptors [63].
Hypovolemia impairs sweating [64], but decreased preload
can cause more than reﬂex bradycardia as demonstrated by
progressive vagal symptoms including sweating, nausea and
syncope [65]. Conversely, hypervolemia does not contribute
to sweating [66].
The profuse sweating may contribute to ﬂuid and elec-
trolyte imbalance, besides considerable energy loss [39]. Also
it aggravates hypothermia which is already resistant to re
warming [7].
Effective atropine management 4014. Limitations of this study
This is an observational prospective study, reporting the efﬁ-
cacy of atropine treatment in spite of low patient’s number.
The low incidence, lake of awareness and unfeasible anticipa-
tion of associations of this phenomenon add difﬁculties in eti-
ological determination. The site of atropine action is not
deﬁned whether it is peripheral on sweat glands or central on
cholinergic pathways. Perioperative records of patients and
room temperatures were not complete.5. Conclusion
Atropine effectively controlled the excessive sweating associ-
ated IT Mo or fentanyl administration in this case series. Fur-
ther randomized studies are recommended to conﬁrm this
effect. The sweating mechanism is not clear. Opioids’ central
thermal, cholinergic and serotonergic effects may be incrimi-
nated. Awareness regards opioids thermal distortions deserve
attention.Conﬂict of Interest
The author declare that there are no conﬂict of interest.References
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